



February 1, 2007

## **Curis to Release Year End and Fourth Quarter 2007 Financial Results and Hold Conference Call on February 14, 2007**

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 1, 2007--Curis, Inc. (NASDAQ: CRIS), a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, will release its year end and fourth quarter financial results on Wednesday, February 14, 2007 before the market opens. The Company will also hold a conference call at 10:00 a.m. Eastern on the 14th to discuss the financial results, progress of its therapeutic product development programs, and additional corporate activities. Daniel Passeri, President and Chief Executive Officer of Curis, will host the call.

To access the live conference call, please call (800) 659-2032 from the United States and Canada or (617) 614-2712 from additional International locations, shortly before 10:00 A.M. The conference ID number is 81229487. Replay will be available approximately two hours after the completion of the call and through 5:00 P.M. EST, Wednesday, February 28, 2007. To access the replay, please call (888) 286-8010 from the United States and Canada or (617) 801-6888 from other locations and reference the conference ID number 50926099.

About Curis, Inc.

Curis is a drug discovery and development company that is committed to leveraging its innovative signaling pathway drug technologies to create new medicines for cancer. In expanding its drug development efforts in the field of cancer through its Targeted Cancer Drug Development Platform, the Company is building upon its previous experiences in targeting signaling pathways in the areas of cancer, neurological disease, hair growth regulation and cardiovascular disease. For more information, please visit [www.curis.com](http://www.curis.com).

CONTACT: Curis, Inc.

Michael P. Gray, 617-503-6632

CFO/COO

[mgray@curis.com](mailto:mgray@curis.com)

or

For Curis, Inc.

Jenny Viscarolasaga, 617-503-6658

[Jenny@tworoadscommunications.com](mailto:Jenny@tworoadscommunications.com)

SOURCE: Curis, Inc.